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Open access under CC BThe enzyme 6-phosphogluconate dehydrogenase is a potential drug target for the parasitic protozoan
Trypanosoma brucei, the causative organism of human African trypanosomiasis. This enzyme has a polar
active site to accommodate the phosphate, hydroxyl and carboxylate groups of the substrate, 6-phospho-
gluconate. A virtual fragment screen was undertaken of the enzyme to discover starting points for the
development of inhibitors which are likely to have appropriate physicochemical properties for an orally
bioavailable compound. A virtual screening library was developed, consisting of compounds with func-
tional groups that could mimic the phosphate group of the substrate, but which have a higher pKa. Fol-
lowing docking, hits were clustered and appropriate compounds purchased and assayed against the
enzyme. Three fragments were identiﬁed that had IC50 values in the low micromolar range and good
ligand efﬁciencies. Based on these initial hits, analogues were procured and further active compounds
were identiﬁed. Some of the fragments identiﬁed represent potential starting points for a medicinal
chemistry programme to develop potent drug-like inhibitors of the enzyme.
 2010 Elsevier Ltd. Open access under CC BY license.OHH
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Human African trypanosomiasis (HAT or sleeping sickness) is
one of the most widespread and lethal tropical diseases on the
African continent.1,2 The causative organisms are the parasites Try-
panosoma brucei rhodesiense and T. b. gambiense. This insect-trans-
mitted infectious disease puts 60 million Africans at risk of death
every year. Current treatments, however, are unsatisfactory due
to toxicity, increasing treatment failures and the need for paren-
teral administration, which is difﬁcult in a rural setting in Africa.
We have previously reported that the enzyme, 6-phosphogluco-
nate dehydrogenase (6PGDH, EC 1.1.1.44), the third enzyme of the
pentose phosphate pathway, is a potential drug target for HAT.3–6
6PGDH catalyses the NADP-dependent oxidative decarboxylation
of 6-phosphogluconate (6PG) to ribulose 5-phosphate (Ru5P).
The catalytic mechanism consists of an acid–base catalysis, which
proceeds with formation of a 3-keto-phosphogluconate, followed
by decarboxylation to the 1,2-enediol high energy intermediate
(HEI) and tautomerisation to the ﬁnal product (Fig. 1). The two
main residues acting as general base and general acid (Glu192
and Lys185, human numbering) are strictly conserved in all spe-ax: +44 1382 386 373 (R.B.);
.).
i.h.gilbert@dundee.ac.uk (I.H.
Y license.cies. Site directed mutagenesis and crystallographic evidence has
proved the essentiality of these residues for enzyme activity.7–10OHH
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Figure 1. Catalytic mechanism of 6PGDH enzyme.
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Figure 2. T. brucei 6PGDH inhibitors reported previously.5,14
G. F. Ruda et al. / Bioorg. Med. Chem. 18 (2010) 5056–5062 5057Expression of T. brucei 6PGDH appears to be essential for viabil-
ity of T. brucei.11 Inhibition of the enzyme diminishes the cellular
pool of NADPH making the parasite more vulnerable to oxidative
stress and increases the levels of 6-phosphogluconate (6PG). 6PG
is known to be a potent inhibitor of glycolysis,12 and as the blood-
stream form of T. brucei relies exclusively on glycolysis as source of
energy, the parasite is very sensitive to disruption of this pathway.
Interestingly, however, 6PGDH depleted trypanosomes are still
susceptible to death when grown using fructose which should by-
pass the lethal feedback loop between glycolysis and 6PG.
We have characterised several T. brucei 6PGDH inhibitors11 and
others are reported in the literature13,14 (Fig. 2). Most of these
inhibitors are phosphorylated carboxylic acids derived from aldose
sugars with poor drug-like properties. The three most potent and
selective compounds are the hydroxamate analogues of the pro-
posed transition state intermediate (compounds A–C, Fig. 2).5 De-
spite their potency (Ki values are in the nanomolar range) and
their selectivity toward the parasite enzyme compared to the
mammalian orthologue, these compounds do not have trypanoci-
dal activity. They are analogues of 4-phospho-D-erythronate, with
a sugar-like backbone, a carboxylic moiety and a phosphate group.
Compounds of this type are predicted to have poor membrane per-
meability due to their charge and polarity.
Crystal structures of human, T. brucei, Lactococcus lactis, and
Geobacillus stearothermophilus 6PGDH have been determined and
deposited in the PDB.7,15–20 All residues that interact with the sub-
strate are fully conserved between Tb6PGDH and Ll6PGDH.
Ll6PGDH, in contrast to Tb6PGDH, was co-crystallised with sub-
strate and inhibitors.
There are two methods in drug discovery, which exploit crystal
structure information for hit discovery: protein structure-based
virtual screening and fragment-based hit discovery.21–24 In pro-
tein-based virtual screening, constraints are derived from the crys-
tal structure and used to ﬁlter in silico libraries for compounds
fulﬁlling these constraints. In fragment-based design, libraries typ-
ically containing small molecules with a molecular weight of less
than 300 Da, and less than three hydrogen-bond donors and six
hydrogen-bond acceptors are screened using biophysical methods
such as X-ray crystallography, nuclear magnetic resonance (NMR)
or surface plasmon resonance (SPR). The resulting hits are often
weak inhibitors with binding constants in the high micromolar to
low millimolar range, but high ligand efﬁciencies. The next stage in
this strategy is to optimise these fragments to more potent com-pounds, by adding substituents which make further binding inter-
actions with the enzyme active site. This process can be facilitated
when the binding modes of the hits and derivatives are determined
crystallographically. It is possible to combine both strategies by
restricting virtual screening to fragment-like libraries.22,25–27
In this paper, we report the virtual fragment screening of
6PGDH with the goal of ﬁnding fragments that are suitable starting
points for a drug discovery programme. A potentially confounding
issue with the active site of 6PGDH is that it contains a large num-
ber of polar residues required for binding to the phosphate, carbox-
ylic acid and hydroxyl groups of the substrate. A corollary of this is
that effective inhibitors targeted against the substrate binding site
are also likely to be polar and hence not very drug-like. We decided
to use the structural information available on 6PGDH to ﬁnd inhib-
itors that have a relatively low polarity and have the correct phys-
icochemical properties to be orally bioavailable. A fragment-based
approach is attractive, as it should allow us to build molecules into
less polar regions of the active site, to derive more ‘drug-like’
inhibitors.
2. Results
The binding sites of Ll6PGDH and Tb6PGDH are highly con-
served but only Ll6PGDH has been co-crystallised with cofactor
and substrate or inhibitor.15 Therefore, we used the latter crystal
structure of Ll6PGDH in complex with NADP+ and PEX (compound
A, Fig. 2) as a template structure for virtual screening.
The 6PGDH-binding site contains a cluster of positively charged
residues, which accommodates the phosphate group of the sub-
strate (Fig. 3A). This part of the active site is deeply buried in the
enzyme active site and not readily accessible by bulk solvent. We
therefore assumed that by targeting this area potent inhibition
can be achieved. Consequently, the docking programme used in
this study (DOCK 3.528,29) was biased to address this part of the
binding site by only placing spheres for ligand matching close to
the cluster of positively charged residues. This set-up was vali-
dated using a set of 36 Tb6PGDH inhibitors5,6,30 (33 moderate
inhibitors plus the three potent compounds A–C). Re-docking
PEX into the Ll6PGDH resulted in a docking pose close to the crys-
tallographically determined binding mode (RMSD 1.16 Å) with the
phosphate group interacting with the two arginine residues (447
and 289) and the Tyr192 hydroxyl group (Fig. 3B). The docking pro-
gramme was also able to generate plausible binding modes for
Figure 3. (A) Ligand PEX in the active site of L. lactis 6PGDH. Putative hydrogen
bonds are indicated by dashed lines. (B) Superposition of the ligand PEX (green
carbon atoms) with the binding mode of the same ligand predicted by the docking
calculations (grey carbon atoms). The RMSD between both posed is 1.16 Å.
5058 G. F. Ruda et al. / Bioorg. Med. Chem. 18 (2010) 5056–5062most inhibitors of the test-set; the phosphate groups of the com-
pounds were placed into the same area where the phosphate group
of PEX binds, albeit no crystal structures were available to compare
the predicted binding poses.
The goal of this study was then to identify new scaffolds for the
potential development of inhibitors of T. brucei 6PGDH by virtual
fragment screening. These fragments could potentially be elabo-
rated to pick up further binding interactions with the enzyme ac-
tive site, and hence increase the potency of inhibition. One key
requirement, for compounds likely to show oral bioavailability,
was to replace the phosphate group found in both the substrate
and known inhibitors (Fig. 2) with functional groups that are less
polar and ‘less ionised’ at physiological pH. The phosphate replace-
ment should still be able to bind strongly to the cluster of posi-
tively charged amino acids known to bind to the phosphate. The
available chemicals and screening compounds directories (ACD–
SCD) were consequently ﬁltered for compounds containing any
of the following functionalities that may be able to mimic the
phosphate: phosphonate, sulfonate, sulfonic acid, sulfonamide,
carboxylic acid, and tetrazole. In addition, the compounds were re-
quired to have a molecular weight of less than 320 Da. Applying
these ﬁlters resulted in a library containing approximately
64,000 compounds.
The ﬁltered sub-set was docked into the Ll6PGDH-binding site
using DOCK 3.5.54 wherein the ligands were forced to place theirnegatively charged functional group into the positively charged
area of the binding site. Out of the 64,000 compounds in the ﬁl-
tered set, binding modes for 5836 compounds were generated.
For the remaining compounds the docking programme was not
able to generate a docking pose due to steric clashes. The 5836 hits
were subsequently clustered using Daylight ﬁngerprints and
ranked within each cluster according to their docking score, result-
ing in around 500 clusters and approximately 400 singletons. High
scoring compounds were visually inspected together with the
compounds belonging to the same cluster and 71 promising com-
pounds were identiﬁed for purchase. Criteria for visual inspection
were quality of hydrogen bonds formed with the amino acids of
the positively charged cluster and diversity of chemical scaffolds.
The selected compounds were evaluated in a biological assay
using the recombinant Tb6PGDH. Initially, percent inhibition of
the compounds were determined at 200 lM. Compounds which
showed a percentage of inhibition equal or greater than 80% were
re-screened at 50 lM (Fig. 5). Finally, IC50 determinations were
carried out on compounds giving >50% inhibition at 50 lM. Three
compounds gave IC50 values in the low micromolar range (Table 1)
and were considered of interest for further study. We were unable
to obtain IC50 values with the remaining compounds (4–10) in Fig-
ure 4 and assume that these were false positives in the initial
screen or that compounds were labile over the storage period.
The ligands 1–3 contain only between 11 and 14 non-hydrogen
atoms and have therefore high ligand efﬁciencies22,31 of 0.4–0.7
[(kcal/mol)/heavy atom], their IC50 curves are also reported in Fig-
ure 6. In the computationally generated binding modes the carbox-
ylate groups of the ligands interact with the positively charged
area in the binding site which previously had been observed to
accommodate the phosphate group of the substrate of substrate-
like inhibitors15 (Fig. 5A–C).
To further validate the initial hits the ACD–SCD database was
searched for commercially available analogues of the hits in Fig-
ure 4. An additional 53 compounds were purchased (together with
hits from the ﬁrst screening) and tested for enzyme inhibition. For
the most active compounds IC50 values were determined (com-
pounds 11–18, Table 1). The compounds 15–18, have Hill slopes
that are much higher than expected for competitive inhibitors
and, most likely, are promiscuous inhibitors.32,33 Compounds 4, 5
and 10, did not conﬁrm the previous reported activity, indicating
that perhaps they were false positives in the ﬁrst screening. The
most potent and interesting hits were compounds 1–3, for which
the IC50 curves are reported in Figure 6 (identiﬁed in the ﬁrst
screening and re-conﬁrmed in the second round) and 11–13 with
IC50 values between 40 and 80 lM, all with ligand efﬁciency higher
than 0.3 (such a ligand efﬁciency is required for compound of
molecular weight 500 Da to have an IC50 value of 10 nM).3. Discussion
6-Phosphogluconate dehydrogenase is a potential drug target
for human African trypanosomiasis. The enzyme has been demon-
strated to be essential by RNAi studies,11 and inhibitors have been
discovered that inhibit the enzyme potently and with good selec-
tivity compared to a mammalian (sheep liver) 6PGDH (Fig. 2).5,14
In order to accommodate the polar substrate, the active site of
6PGDH is correspondingly polar (Fig. 3A). The inhibitors that we
have previously developed5 are based around the substrate and
are polar themselves. Whilst they are potent inhibitors of the en-
zyme, they lack drug-like properties, in particular cellular perme-
ability. We have published a prodrug approach for selective
delivery of these compounds which demonstrates how even highly
polar compounds have potential for development as drugs.4 An
alternative strategy, for a discovery process, is to search for new
Figure 5. Docking poses for compound 1 (A), compound 2 (B) and compound 3 (C) in the active site of L. lactis.
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we report an approach to do this by selecting an in silico library of
fragments from commercially available compounds and then car-
rying out a virtual screen of the library. From the hits identiﬁed
by the computational work, compounds were purchased and
tested for inhibition of the enzyme. Information from the ﬁrst
round of testing was used to guide a second round of compound
purchase. Future work should now focus on building upon the frag-
ment scaffolds in order to increase their potency as inhibitors, tak-
ing advantage of other interactions within the enzyme’s active site,and ultimately to develop them as compounds with better drug-
like properties.
Virtual screening of the fragment library and subsequent pur-
chase and testing of analogues identiﬁed several ligands with
IC50 values in the low micromolar range, and with high ligand efﬁ-
ciencies (Table 1). Except for compound 4, all of the ligands have a
carboxylate group as a replacement for the phosphate; in the gen-
erated binding modes the carboxylate mimics the phosphate group
(Fig. 5). Examples of a carboxylate group mimicking phosphate
interactions have already been found in the past for various cases,
Table 1
IC50 values, Hill slopes, ligand efﬁciency (RTLn(IC50)/HAC)31 and predicted solubility, log P, log D, human intestinal absorption (HIA) and TPSA using StarDrop
Compd Structure IC50 (lM) Hill slope Ligand efﬁciency [(kcal/mol)/HAC] Log S Log P Log D HIA TPSA
1
O
O
H
N
O
HO
45 ± 11 1.6 0.40 3.3 1.7 1.1 + 79
2
H
N
O
HO
Cl
43 ± 9 1.8 0.66 4.3 1.4 1.6 + 53
3
O N
+
O
O-
HO
O
28 ± 6 1.5 0.52 4.2 1.1 1.4 + 96
11 NOH
O
SNaO
O
O
73 ± 9 1.4 0.33 2.4 0.7 0.7 + 93
12
SOO
HO
O
51 ± 3 1.7 0.42 3.2 1.2 1.1 + 68
13
HN
SHO
O
42 ± 7 1.1 0.54 3.4 1.5 1.2 + 53
14
H
N
H
N OHHO
O O
114 ± 27 1.4 0.27 2.6 2.1 1.1 + 106
15 O
NO2
HO
O
OHO
56 ± 6 5.2 0.36 3.4 1.3 3.2 + 134
16 O
O
SKO
O
O
53 ± 4 4.8 0.36 2.2 0.2 0.2 + 78
17 O
NO2NC
HO
O
5.8 ± 0.6 2.0 0.48 3.4 0.9 1.9 + 120
18
H
N
O
HO
Cl
Cl
42 ± 3.7 2.1 0.60 3.9 2.0 1.1 + 53
HAC: heavy atom count.
StarDrop: (www.optibrium.com).
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the phosphate group a carboxylic group has the advantage that the
pKa is much higher (2 for phosphate vs 5 for carboxylate) and
the discovered hits have therefore a much better chance of being
membrane permeable.
Interestingly other functional groups selected for the screening
(tetrazole and sulfonamides) did not produce good hits. This could
probably be explained considering the higher chemical diversitypresent among the carboxylic acids, which were higher in number
compared to the tetrazoles and sulfonamides in the starting
database.
Solubility, partition coefﬁcients, TPSA and human intestinal
absorption (HIA) were calculated using the software Stardrop
(Optibrium Ltd, Cambridge, UK) and are reported in Table 1. Com-
parison of these predictions with those for the known inhibitors,
reported in Table 2, clearly shows how the new scaffolds constitute
Figure 6. IC50 curves for the compounds 1–3.
Table 2
StarDrop predictions for the known inhibitors AC
Log S Log P Log D HIA category MW HBD HBA TPSA
A 5.4 0.9 2.2 + 315 4 11 169
B 5.6 0.2 2.5  271 4 9 135
C 6.2 1.8 3.9  231 6 9 157
StarDrop: (www.optibrium.com).
G. F. Ruda et al. / Bioorg. Med. Chem. 18 (2010) 5056–5062 5061an improvement in the drug-likeness of the molecules. The parti-
tion coefﬁcients are higher for compounds 1–18 than the corre-
sponding values for the inhibitors A–C, indicating a higher
likelihood of passive diffusion. Similarly, in general, the TPSA val-
ues are more reasonable for an orally bioavailable compound. Hu-
man intestinal absorption (HIA) is also estimated, as a predictor for
oral bioavailability. This is a positive value (predicted absorption is
P30%) for all the hits in Table 1 whereas compounds B and C have
negative signs, again indicating a low likelihood of oral
bioavailability.
From the chemistry point of view the aldose sugar moiety could
be replaced with some ﬁve-membered heterocycles (compounds
1–3) or fused ﬁve/six-membered rings (compounds 12 and 13)
indicating that the binding pocket is large enough to accommodate
these types of structures. This ﬁnding is also supported by the fact
that 6-aminonicotinamide35 was reported as a potential inhibitor
of 6PGDH, although this compound might bind to the cofactor
binding site. These new heterocyclic scaffolds constitute valuable
starting points for further optimisation and give the opportunity
to explore new, tractable, chemistry routes. By building towards
the less polar cofactor binding site and exploiting additional inter-
actions with the enzyme it should be possible to improve their
afﬁnities. The generated docking poses can serve as guidelines
for structure-based design to support this process. However, dur-
ing docking the ligands were forced to place their charged group
into the area with which the phosphate groups of substrate and
substrate-like inhibitors interact. Unrestrained docking of the hits
discovered here into the 6PG binding site indicated that alternative
interactions of the carboxylate group with the area in which the
carboxylate group of the substrate binds could also be possible. At-
tempts are therefore underway to determine crystallographically
the binding modes of the discovered hits.
4. Conclusions
Virtual screening successfully identiﬁed new scaffolds, which
can bind to the Tb6PGDH active site. The 6PGDH active site is polar,
yet the compounds that we have discovered include some less po-
lar molecules that have good ligand efﬁciencies (>0.3 kcal/mol/(HAC)) and promising physicochemical and predicted ADME prop-
erties. Some of the hits are chemically tractable and have the po-
tential to be elaborated further to drug-like molecules.
5. Methods
5.1. Compound selection and quality control
The ACD–SC library was screened for molecules which have a
molecular weight of less than 320 Da and which contain at least
one of the following negatively charged functional groups: phos-
phonate, sulfonate, sulfonic acid, sulfonamide, carboxylic acid,
bicarboxylic acid or tetrazole.
The search was carried out through the DiscoveryGate webser-
vice (Symyx Technologies Inc.) on the ACD–SC database. The sec-
ond selection of compounds was carried out by using a similarity
index of 80 in respect to the structures of the hits identiﬁed in
the screening.
Once purchased the compounds were tested for quality control
by LC–MS on a Bruker Microtof spectrometer. The compounds
eluted through a Waters Xbridge column (5  50 mm), with a gra-
dient of 5–95% ACN/water +0.1% ammonia and they showed a pur-
ity >95%.5.2. Computational methods
DOCK 3.5.5428,29 was used to dock small molecules into the
active site of Ll6PGDH. In short, DOCK 3.5.54 uses a hierarchical
database format to dock conformational ensembles of small mol-
ecules into protein sites.27 The conformations of a given mole-
cule are pre-calculated and superimposed on a rigid common
fragment, which is usually a ring system. The ligand conformers
are then docked together, as an ensemble, into a receptor bind-
ing site by matching the atoms of the common fragment to
receptor spheres. In the current study, we wanted to generate
only ligand poses in which the functional groups intended to re-
place the phosphate group were placed in the phosphate binding
site. To achieve this, the following changes were made to our
standard receptor and database preparation procedures pub-
lished earlier:25 (1) Instead of superimposing the small molecule
ensembles on the ring systems the phosphate isostere groups
were used as common fragments for compound alignment and
matching. (2) Spheres used for receptor matching positions for
docking were only placed in the binding site in the area that
was occupied by phosphate group of the inhibitor.
The crystal structure of Ll6PGDH in complex with cofactor and
PEX (2IZ0) was chosen as template structure.15 The protonation
states of the two catalytically important residues Lys184 and
5062 G. F. Ruda et al. / Bioorg. Med. Chem. 18 (2010) 5056–5062Glu191 changes following the reaction coordinate. Here, we only
considered the protonation states which are required to bind the
substrate, in particular, Lys184 was considered to be positively
charged and Glu191 to be neutral.
To facilitate visual inspection all compounds for a binding mode
was generated were clustered using the Jarvis–Patrick algorithm of
the Daylight clustering package (Daylight, Aliso Viejo, USA)
whereas compounds had to have at least 10 of 16 neighbours in
common in order to be allowed to belong the same cluster and
compounds for which the nearest neighbour had a Tanimoto coef-
ﬁcient of less than 0.8 were classiﬁed as singletons.
5.3. Assay
The T. brucei 6PGDH expressed in E. coli was puriﬁed as de-
scribed.36 Inhibition studies involved a reaction in 50 mM trietha-
nolamine pH 7.0, 2 mM MgCl2. NADPH and 6PG were each at
20 lM. Total reaction volume was 1 ml. The reaction was followed
in a Perkin Elmer UV–vis spectrophotometer. Compounds were
dissolved in DMSO and initially added at 200 lM, then 50 lM.
Any compound giving more than 50% inhibition at 50 lMwas used
to determine IC50 values over a range of substrates (doubling dilu-
tions from 200 lM).
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